Study guide

7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

Key Takeaways Explain This Topic AI

Urethritis in men is treated empirically for gonorrhea and chlamydia (ceftriaxone 500 mg IM plus doxycycline 100 mg twice daily for 7 days), and partners within 60 days need evaluation or expedited partner therapy.

Acute epididymitis from likely STI is treated with ceftriaxone plus 10 days of doxycycline; men who practice insertive anal sex also need coverage for enteric organisms, such as levofloxacin.

Varicocele is the most common correctable cause of male infertility, and exogenous testosterone or anabolic steroids suppress spermatogenesis and can cause azoospermia.

PDE5 inhibitors for erectile dysfunction are contraindicated with nitrates because of profound hypotension, and erectile dysfunction is a marker of cardiovascular disease.

The USPSTF recommends against routine testicular cancer screening and leaves PSA screening at ages 55–69 to shared decision-making.

Last updated: October 2026

Why Male Health Is on a Women's Health Exam

NCC's outline lists "Sexual and Reproductive Health for Males" (sexuality, contraception, infertility, STIs) within the gynecology domain. WHNPs treat partners through expedited partner therapy (EPT), evaluate couples with infertility, and counsel on shared contraceptive decisions.

STI Syndromes in Men

Syndrome Typical Presentation CDC-Recommended Management

Urethritis Dysuria, urethral discharge, itching Test by NAAT (first-catch urine); empiric ceftriaxone 500 mg IM (1 g if 150 kg or more) plus doxycycline 100 mg twice daily for 7 days ; consider M. genitalium or trichomoniasis if symptoms persist

Acute epididymitis Gradual unilateral scrotal pain and swelling, tender epididymis Likely gonorrhea or chlamydia: ceftriaxone 500 mg IM plus doxycycline 100 mg twice daily for 10 days . Insertive anal sex: ceftriaxone plus levofloxacin for 10 days. Enteric organisms only (for example, after urinary instrumentation): levofloxacin alone

Proctitis (receptive anal sex) Rectal pain, discharge, tenesmus Ceftriaxone plus doxycycline for 7 days (21 days if lymphogranuloma venereum is suspected)

Genital ulcers Painful ulcers suggest HSV; a painless indurated ulcer suggests syphilis Test for HSV (PCR) and syphilis (serology); treat by etiology

Trichomoniasis Often asymptomatic urethritis Metronidazole 2 g orally once (the 7-day course is for women)

Partner management: Partners from the previous 60 days should be evaluated. Where permitted by state law, EPT gives the patient medication for the partner; for gonorrhea, EPT for the partner is cefixime 800 mg orally once (plus doxycycline if chlamydia is not excluded). Retest everyone with gonorrhea or chlamydia at 3 months.

Prevention for Men Who Have Sex with Men

Screen for gonorrhea and chlamydia at every exposed site (urethral, rectal, pharyngeal) at least annually, along with syphilis and HIV; screen every 3–6 months when risk is higher.

Offer HIV PrEP, hepatitis A and B vaccination, and HPV vaccination through age 26 (shared decision-making to 45).

Doxycycline post-exposure prophylaxis (200 mg within 72 hours after condomless sex) is recommended for men who have sex with men and transgender women with a bacterial STI in the past year.

Male Infertility

Male factor contributes to about 40%–50% of infertile couples, so a semen analysis belongs in the first visit (collected after 2–7 days of abstinence; see the infertility section for WHO 6th-edition limits).

Cause Features

Varicocele Most common correctable cause; left-sided "bag of worms"; impairs sperm through raised scrotal temperature

Exogenous testosterone or anabolic steroids Suppress pituitary LH and FSH, shutting down spermatogenesis and causing azoospermia ; recovery after stopping can take months

Primary testicular failure Small testes, high FSH ; includes Klinefelter syndrome (47,XXY) and Y-chromosome microdeletions

Hypogonadotropic hypogonadism Low FSH, LH, and testosterone (Kallmann syndrome, pituitary disease, opioids)

Obstruction Normal testes and FSH with azoospermia; congenital bilateral absence of the vas deferens points to CFTR variants, so test the female partner for cystic fibrosis carrier status

Lifestyle Heat exposure, smoking, heavy alcohol or cannabis use, obesity, and some medications

Men with low testosterone who want future fertility should not receive testosterone; clomiphene, hCG, or anastrozole (off-label) can raise endogenous testosterone while preserving sperm production.

Male Contraception

Condoms (external): the only male method that also prevents STIs; typical-use failure about 13% per year.

Withdrawal: Typical-use failure about 20% per year.

Vasectomy: Highly effective permanent method; not effective until a post-vasectomy semen analysis at 8–16 weeks shows azoospermia or rare nonmotile sperm.

No hormonal male method is FDA-approved; combination gels such as nestorone/testosterone remain in clinical trials.

Erectile Dysfunction and Other Concerns

Erectile dysfunction (ED) is a sentinel marker of cardiovascular disease , because penile arteries are small and endothelial dysfunction shows there early. Assess blood pressure, lipids, glucose, smoking, depression, and medications such as thiazides, beta-blockers, SSRIs, and antiandrogens.

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are first-line. They are contraindicated with nitrates (and riociguat) because of profound hypotension; use caution with alpha-blockers. An erection lasting more than 4 hours ( priapism ) is an emergency.

Hypogonadism: Diagnose only with symptoms plus two early-morning total testosterone levels below about 300 ng/dL (AUA).

Premature ejaculation: Behavioral techniques, topical anesthetics, or off-label daily or on-demand SSRIs.

Preventive Screening for Men

Topic Recommendation

Testicular cancer USPSTF recommends against routine screening of asymptomatic men (grade D); teach men to report any testicular mass

Prostate cancer PSA screening at ages 55–69 is an individual decision (grade C); not recommended at 70 and older (grade D)

  • HIV, hepatitis B and C, syphilis Same universal adult and risk-based screening as for women
  • HPV vaccination Through age 26; shared decision-making for ages 27–45
  • Working with Couples

In infertility care, evaluate both partners at the first visit: a semen analysis is inexpensive and noninvasive and can redirect the entire workup.

When treating a woman for an STI, ask about partners, offer expedited partner therapy where state law permits, and advise abstinence until both partners finish treatment.

Shared contraceptive decisions work best when both partners understand failure rates, vasectomy as an option, and the need for condoms to prevent STIs.